Vogenx (NASDAQ:VOGX) Issues Earnings Results, Beats Estimates By $0.01 EPS

Vogenx (NASDAQ:VOGX) announced its earnings results on Friday. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, Zacks reports.

Vogenx Stock Performance

VOGX traded down $0.78 during trading hours on Friday, hitting $17.45. 66,333 shares of the company’s stock were exchanged, compared to its average volume of 147,027. The company has a market capitalization of $259.13 million and a PE ratio of -249.29. Vogenx has a 1-year low of $12.95 and a 1-year high of $38.41. The firm has a 50-day moving average price of $23.77.

Analyst Upgrades and Downgrades

Several analysts have issued reports on VOGX shares. WBB Securities assumed coverage on Vogenx in a research note on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price target on the stock. Zacks Research raised Vogenx to a “hold” rating in a research report on Monday, September 28th. JonesTrading initiated coverage on Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective for the company. Finally, Wall Street Zen raised Vogenx to a “hold” rating in a research report on Saturday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $48.50.

About Vogenx

Vogenx, Inc is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company has historically concentrated on small-molecule drug candidates intended to address conditions in which existing treatment options may be limited.

Vogenx’s lead development program has included VGX-1027, an investigational anti-inflammatory compound studied for its potential to regulate abnormal immune responses. Research involving the candidate has focused on diseases associated with inflammation and immune-system dysfunction, although its development status and commercial availability may change over time.

The company’s activities have primarily involved pharmaceutical research and development rather than the marketing of an established portfolio of products.